Previous 10 |
Biomerica (NASDAQ: BMRA ): Q3 GAAP EPS of -$0.07 misses by $0.02 . More news on: Biomerica, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
The USPTO has issued a Notice of Allowance for Biomerica’s (NASDAQ: BMRA ) first U.S. patent pertaining to the Company’s InFoods family of products that allow for new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal d...
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of p...
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. Based on recent discussions between Biomerica and the United States Food an...
News, Short Squeeze, Breakout and More Instantly...
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarter...
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in p hysicians prescribing i nFoods more than doubled each quarter over the past 12 months. - Bio...
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syn...